The potential use of SCF for treatment of β-thalassemic or sickle cell anemia patients implies a chronic administration protocol, based on sequential intermittent therapy cycles: this protocol may amplify the potential risk of allergic reactions and must be considered cautiously in view of these possible side effects. The gene discussed is KITLG; the disease is sickle cell disease.